
Prothena Therapeutics has acted drastically by slashing staff numbers by more than half, after the failure of two pivotal trials …

Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

